医药商业行业并购估值中市场法的运用（资料）.docVIP

医药商业行业并购估值中市场法的运用（资料） 目录 TOC \o 1-9 \h \z \u 目录 1 正文 1 文1：医药商业行业并购估值中市场法的运用 1 Abstract 1 第 1 章 绪论 3 、研究目的和意义。 4 （1）市场法可比公司研究。 6 （2）市场法价值乘数研究。 6 、估值方法研究。 7 【由于本篇文章为硕士论文，如需全文请点击底部全文链接】 9 、医药生物行业并购估值概况 9 、市场法模型价值估值 10 、本章小结 10 第五章 研究结论 10 文2：国内外医药商业行业发展比较 11 参考文摘引言： 16 原创性声明（模板） 17 文章致谢（模板） 17 正文 医药商业行业并购估值中市场法的运用（资料） 文1：医药商业行业并购估值中市场法的运用 Abstract Favorable national policies and inteified competitive environment are driving the pharmaceutical biotechnology industry to expand through the capital market. The accelerated industry concentration is reflected in the boom in merge and acquisitio (MAs)， in which the valuation results provide an important basis for pricing. Hence， due attention is deserved in regard to the ways to choose a reasonable valuation method. Over the past few yea， China’s capital market has been growing and improving， especially in the pharmaceutical biotechnology industry. As more and more companies go public， the prerequisites are gradually in place for the application of the market-based method。 Among the three major methods of corporate value evaluation， the market-based method is advantageous in terms of operational simplicity and ease of undetanding. However， it is not widely adopted in the MA valuation of the pharmaceutical bio-industry. This paper believes that such a situation is tightly connected with the single choice of value multiplie and the judgment subjectivity of the market-based method. So it is key to find ways to choose rational value multiplie to broaden the adoption of the market-based method. To overcome the shortcomings of value multiplier selection of the market-based method， the paper takes account of the industry characteristics and discusses value drive from multiple pepectives to address the problem of single choice of value multiplie. Meanwhile， the paper introduces the principal component analysis method in weighting the selected value multiplie， and applies statistica